Aravive Appoints Scott Dove, Ph.D., as Chief Operating Officer
March 22 2022 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology
company developing targeted therapeutics to treat metastatic
disease, today announced the appointment of industry veteran, Scott
Dove, Ph.D., as Chief Operating Officer.
“We are honored Dr. Dove is bringing his strong industry, drug
development, and leadership experience to Aravive,” said Gail
McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “The
next 12 months promises to be the most data-rich period in the
Company’s history. Scott will be pivotal in executing the steady
stream of anticipated clinical milestones across each of our three
ongoing clinical programs for batiraxcept.”
Dr. Dove has more than twenty years of experience in drug
development. Previously, he served as Senior Vice President and
General Manager at PPD, where he provided strategic direction and
oversight of PPD’s Early Development Services business unit. In
this role, Dr. Dove was responsible for the organizational design
and executive management of early phase CRO operations. Prior to
joining PPD, he was an Executive Director of Clinical Development
with Allergan, serving as global clinical development leader for
Viberzi®/Truberzi® (eluxadoline). At Allergan, he negotiated
marketing approvals, labeling, and post-marketing requirements for
eluxadoline as a treatment for irritable bowel syndrome, while
overseeing the development and operational execution of its label
expansion and lifecycle management clinical strategy. He previously
oversaw the development of eluxadoline as program leader at Furiex
Pharmaceuticals, Inc., managing the program through successful NDA
submission until the acquisition of Furiex by Actavis plc (now
Allergan). Dr. Dove received his B.S. in biochemistry and a
doctorate in pharmacology from Texas A&M University.
“I am excited to join Aravive at this pivotal time for the
Company, with its lead compound, batiraxcept, being evaluated in
multiple clinical trials, including a registrational Phase 3 trial
in platinum-resistant ovarian cancer, a Phase 1b/2 trial in clear
cell renal cancer and a Phase 1b trial in pancreatic cancer,” said
Dr. Dove. “Topline data from the Phase 3 trial in
platinum-resistant ovarian cancer are expected in the second
quarter of 2023 and the recent biomarker data from the Phase 1b
trial in clear cell renal cancer are compelling. I look forward to
working with the team to advance all of these programs to maximize
the value of batiraxcept for patients and shareholders.”
About AraviveAravive, Inc. is
a late clinical-stage oncology company developing targeted
therapeutics to treat metastatic disease. Our lead product
candidate, batiraxcept (formerly AVB-500), is an ultra-high
affinity decoy protein that binds to GAS6, the sole ligand that
activates AXL, thereby inhibiting metastasis and tumor growth, and
restoring sensitivity to anti-cancer agents. Batiraxcept has been
granted Fast Track Designation by the U.S. FDA and Orphan Drug
Designation by the European Commission in platinum-resistant
recurrent ovarian cancer. Batiraxcept is in an active
registrational Phase 3 trial in platinum resistant ovarian cancer
(NCT04729608), a Phase 1b/2 trial in clear cell renal cell
carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic
adenocarcinoma (NCT04983407). Additional information
at www.aravive.com.
Contact:Marek Ciszewski, J.D.Vice President,
Investor Relationsmciszewski@araive.com(562) 373-5787
Forward-Looking StatementsThis
press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 on
our current expectations and projections about future events. In
some cases, forward-looking statements can be identified by
terminology such as “may,” “should,” “potential,” “continue,”
“expects,” “anticipates,” “intends,” “plans,” “believes,”
“estimates,” and similar expressions, and include statements
regarding the next 12 months promising to be the most data-rich
period in the Company’s history, providing data from the Phase 3
trial in platinum-resistant ovarian cancer in the second quarter of
2023, advancing all of the programs to maximize the value of
batiraxcept for patients and shareholders. Forward-looking
statements are based on current beliefs and assumptions, are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results to differ materially
from those contained in any forward-looking statement as a result
of various factors, including, but not limited to, risks and
uncertainties related to: the ability to provide data when
anticipated and reach anticipated milestones, the data from
patients treated in the future with batiraxcept being consistent
with the results reported, the ability to enroll the expected
number of patients, the impact of COVID-19 on the Company's
clinical strategy, clinical trials, supply chain and fundraising,
the Company's ability to expand development into additional
indications, the Company's dependence upon batiraxcept,
batiraxcept’s ability to have favorable results in clinical trials
and ISTs, the clinical trials of batiraxcept having results that
are as favorable as those of preclinical and clinical trials, the
ability to receive regulatory approval, potential delays in the
Company's clinical trials due to regulatory requirements or
difficulty identifying qualified investigators or enrolling
patients especially in light of the COVID-19 pandemic; the risk
that batiraxcept may cause serious side effects or have properties
that delay or prevent regulatory approval or limit its commercial
potential; the risk that the Company may encounter difficulties in
manufacturing batiraxcept; if batiraxcept is approved, risks
associated with its market acceptance, including pricing and
reimbursement; potential difficulties enforcing the Company's
intellectual property rights; the Company's reliance on its
licensor of intellectual property and financing needs. The
foregoing review of important factors that could cause actual
events to differ from expectations should not be construed as
exhaustive and should be read in conjunction with statements that
are included herein and elsewhere, including the risk factors
included in the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2020, recent Current Reports on Form 8-K
and subsequent filings with the SEC. Except as required by
applicable law, the Company undertakes no obligation to revise or
update any forward-looking statement, or to make any other
forward-looking statements, whether as a result of new information,
future events or otherwise.
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2023 to Sep 2024